Theriva Biologics Files 8-K
Ticker: TOVX · Form: 8-K · Filed: Oct 6, 2025 · CIK: 894158
| Field | Detail |
|---|---|
| Company | Theriva Biologics, Inc. (TOVX) |
| Form Type | 8-K |
| Filed Date | Oct 6, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, financials
TL;DR
Theriva Biologics filed an 8-K on 10/6/25 covering Reg FD, other events, and financials.
AI Summary
Theriva Biologics, Inc. filed an 8-K on October 6, 2025, reporting on events that occurred on the same date. The filing includes information related to Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The company, formerly known as Synthetic Biologics, Inc., is incorporated in Nevada and its fiscal year ends on December 31st.
Why It Matters
This 8-K filing indicates Theriva Biologics is making disclosures to the SEC, which could involve significant corporate events or financial updates that investors should monitor.
Risk Assessment
Risk Level: low — This filing is a routine 8-K report and does not inherently indicate significant new risks.
Key Players & Entities
- Theriva Biologics, Inc. (company) — Registrant
- October 6, 2025 (date) — Date of earliest event reported
- Synthetic Biologics, Inc. (company) — Former company name
- Nevada (jurisdiction) — State of incorporation
FAQ
What specific events are being disclosed under Regulation FD?
The filing does not specify the exact events covered under Regulation FD, only that it is a disclosure.
What are the 'Other Events' being reported by Theriva Biologics?
The filing does not detail the specific 'Other Events' that are being reported.
What is the significance of filing 'Financial Statements and Exhibits' in this 8-K?
This indicates that financial information or related exhibits are being provided as part of the report, though the specifics are not detailed in the provided text.
When was Theriva Biologics previously known as Synthetic Biologics, Inc.?
The filing states the date of name change from Synthetic Biologics, Inc. was March 5, 2012.
What is Theriva Biologics' fiscal year end?
Theriva Biologics' fiscal year ends on December 31st.
Filing Stats: 633 words · 3 min read · ~2 pages · Grade level 11.1 · Accepted 2025-10-06 08:10:32
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share TOVX NYSE American Indica
Filing Documents
- tm2528055d1_8k.htm (8-K) — 28KB
- tm2528055d1_ex99-1.htm (EX-99.1) — 15KB
- tm2528055d1_ex99-1img001.jpg (GRAPHIC) — 5KB
- 0001104659-25-096946.txt ( ) — 218KB
- syn-20251006.xsd (EX-101.SCH) — 3KB
- syn-20251006_lab.xml (EX-101.LAB) — 33KB
- syn-20251006_pre.xml (EX-101.PRE) — 22KB
- tm2528055d1_8k_htm.xml (XML) — 4KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On October 6, 2025, Theriva Biologics, Inc. (the "Company") issued a press release announcing the presentation at the 32 nd Annual Congress of the European Society of Gene & Cell Therapy of preclinical data for VCN-12, a next generation oncolytic adenovirus developed as part of Theriva's VCN-X discovery program. The press release also announced publication of the results of a preclinical study evaluating the intracranial administration of VCN-01, which supports the further development thereof for the potential treatment of brain tumors. The information in this Item 7.01 furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended and shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
01. Other Events
Item 8.01. Other Events. On October 6, 2025, the Company issued a press release announcing a publication of the results of a preclinical study conducted by collaborators at the University of Navarra evaluating the intracranial administration of VCN-01, which supports the further development thereof for the potential treatment of brain tumors.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release issued by Theriva Biologics, Inc., dated October 6, 2025 104 Cover Page Interactive Data File (embedded within the XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: October 6, 2025 THERIVA BIOLOGICS, INC. By: /s/ Steven A. Shallcross Name: Steven A. Shallcross Title: Chief Executive Officer and Chief Financial Officer